MaxCyte IncNASDAQ:MXCT
- LAST PRICE4.7350
- TODAY'S CHANGE (%)0.1950 (4.2952%)
- Bid / Lots4.7300/ 3
- Ask / Lots4.7400/ 6
- Open / Previous Close4.5800 / 4.5400
- Day Range
- 52 Week Range
- Volume238,350
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MXCT |
|---|---|---|
| 09:32 ET | 1723 | 4.6177 |
| 09:34 ET | 200 | 4.595 |
| 09:36 ET | 400 | 4.63 |
| 09:38 ET | 500 | 4.6 |
| 09:39 ET | 1300 | 4.58 |
| 09:41 ET | 5100 | 4.59 |
| 09:43 ET | 300 | 4.58 |
| 09:45 ET | 100 | 4.57 |
| 09:48 ET | 699 | 4.59 |
| 09:50 ET | 100 | 4.585 |
| 09:52 ET | 1800 | 4.62 |
| 09:54 ET | 4159 | 4.665 |
| 09:56 ET | 337 | 4.68 |
| 09:57 ET | 1343 | 4.71 |
| 09:59 ET | 2412 | 4.705 |
| 10:01 ET | 1606 | 4.71 |
| 10:03 ET | 537 | 4.72 |
| 10:06 ET | 1003 | 4.73 |
| 10:08 ET | 2041 | 4.725 |
| 10:10 ET | 200 | 4.725 |
| 10:12 ET | 1600 | 4.705 |
| 10:14 ET | 3737 | 4.685 |
| 10:15 ET | 1187 | 4.675 |
| 10:17 ET | 300 | 4.68 |
| 10:19 ET | 1056 | 4.6865 |
| 10:21 ET | 2750 | 4.66 |
| 10:24 ET | 1200 | 4.665 |
| 10:26 ET | 5569 | 4.605 |
| 10:28 ET | 3310 | 4.63 |
| 10:30 ET | 1000 | 4.63 |
| 10:32 ET | 6665 | 4.605 |
| 10:33 ET | 1000 | 4.59 |
| 10:35 ET | 460 | 4.5888 |
| 10:37 ET | 8922 | 4.57 |
| 10:39 ET | 4886 | 4.56 |
| 10:42 ET | 400 | 4.555 |
| 10:44 ET | 2564 | 4.55 |
| 10:46 ET | 1299 | 4.57 |
| 10:48 ET | 860 | 4.5612 |
| 10:50 ET | 100 | 4.56 |
| 10:51 ET | 300 | 4.565 |
| 10:53 ET | 200 | 4.56 |
| 10:55 ET | 32435 | 4.66 |
| 10:57 ET | 200 | 4.67 |
| 11:00 ET | 1693 | 4.68 |
| 11:02 ET | 334 | 4.69 |
| 11:04 ET | 691 | 4.68 |
| 11:06 ET | 500 | 4.695 |
| 11:08 ET | 2573 | 4.705 |
| 11:09 ET | 412 | 4.695 |
| 11:11 ET | 440 | 4.71 |
| 11:13 ET | 3986 | 4.71 |
| 11:15 ET | 100 | 4.705 |
| 11:18 ET | 1200 | 4.68 |
| 11:20 ET | 300 | 4.675 |
| 11:22 ET | 1100 | 4.67 |
| 11:24 ET | 800 | 4.685 |
| 11:26 ET | 100 | 4.685 |
| 11:27 ET | 400 | 4.685 |
| 11:29 ET | 400 | 4.69 |
| 11:31 ET | 100 | 4.695 |
| 11:33 ET | 100 | 4.7 |
| 11:38 ET | 200 | 4.705 |
| 11:40 ET | 1500 | 4.685 |
| 11:42 ET | 600 | 4.68 |
| 11:44 ET | 1289 | 4.705 |
| 11:47 ET | 100 | 4.705 |
| 11:49 ET | 616 | 4.705 |
| 11:51 ET | 500 | 4.705 |
| 11:54 ET | 100 | 4.705 |
| 11:56 ET | 518 | 4.705 |
| 11:58 ET | 700 | 4.72 |
| 12:02 ET | 1400 | 4.715 |
| 12:03 ET | 1700 | 4.695 |
| 12:07 ET | 300 | 4.695 |
| 12:09 ET | 785 | 4.7 |
| 12:12 ET | 592 | 4.71 |
| 12:16 ET | 500 | 4.715 |
| 12:18 ET | 700 | 4.725 |
| 12:20 ET | 600 | 4.735 |
| 12:23 ET | 1815 | 4.755 |
| 12:25 ET | 200 | 4.755 |
| 12:27 ET | 813 | 4.765 |
| 12:30 ET | 400 | 4.77 |
| 12:32 ET | 100 | 4.77 |
| 12:34 ET | 100 | 4.77 |
| 12:36 ET | 100 | 4.77 |
| 12:38 ET | 1200 | 4.755 |
| 12:41 ET | 800 | 4.76 |
| 12:43 ET | 996 | 4.74 |
| 12:45 ET | 257 | 4.745 |
| 12:48 ET | 200 | 4.745 |
| 12:50 ET | 778 | 4.745 |
| 12:52 ET | 865 | 4.76 |
| 12:54 ET | 2300 | 4.755 |
| 12:56 ET | 100 | 4.755 |
| 12:57 ET | 1393 | 4.745 |
| 12:59 ET | 2072 | 4.755 |
| 01:01 ET | 1501 | 4.74 |
| 01:03 ET | 100 | 4.74 |
| 01:06 ET | 200 | 4.745 |
| 01:08 ET | 100 | 4.745 |
| 01:10 ET | 100 | 4.75 |
| 01:14 ET | 100 | 4.745 |
| 01:17 ET | 100 | 4.75 |
| 01:21 ET | 1300 | 4.735 |
| 01:24 ET | 700 | 4.73 |
| 01:26 ET | 100 | 4.72 |
| 01:28 ET | 798 | 4.735 |
| 01:33 ET | 1200 | 4.725 |
| 01:35 ET | 700 | 4.735 |
| 01:42 ET | 792 | 4.735 |
| 01:44 ET | 1019 | 4.725 |
| 01:46 ET | 200 | 4.725 |
| 01:48 ET | 300 | 4.725 |
| 01:51 ET | 100 | 4.725 |
| 01:53 ET | 200 | 4.725 |
| 01:55 ET | 100 | 4.725 |
| 01:57 ET | 1976 | 4.695 |
| 02:00 ET | 1956 | 4.705 |
| 02:02 ET | 300 | 4.72 |
| 02:04 ET | 500 | 4.72 |
| 02:09 ET | 500 | 4.715 |
| 02:13 ET | 100 | 4.72 |
| 02:15 ET | 100 | 4.72 |
| 02:18 ET | 7050 | 4.725 |
| 02:20 ET | 200 | 4.725 |
| 02:22 ET | 100 | 4.725 |
| 02:24 ET | 1452 | 4.725 |
| 02:26 ET | 586 | 4.74 |
| 02:29 ET | 685 | 4.734 |
| 02:31 ET | 3917 | 4.745 |
| 02:33 ET | 400 | 4.74 |
| 02:36 ET | 1500 | 4.725 |
| 02:38 ET | 1926 | 4.715 |
| 02:40 ET | 1130 | 4.735 |
| 02:47 ET | 2700 | 4.715 |
| 02:49 ET | 300 | 4.71 |
| 02:54 ET | 300 | 4.72 |
| 02:56 ET | 600 | 4.72 |
| 02:58 ET | 400 | 4.73 |
| 03:00 ET | 200 | 4.73 |
| 03:03 ET | 2900 | 4.725 |
| 03:09 ET | 100 | 4.73 |
| 03:12 ET | 100 | 4.725 |
| 03:14 ET | 100 | 4.725 |
| 03:16 ET | 100 | 4.73 |
| 03:18 ET | 400 | 4.735 |
| 03:20 ET | 400 | 4.73 |
| 03:21 ET | 100 | 4.735 |
| 03:25 ET | 200 | 4.74 |
| 03:27 ET | 200 | 4.735 |
May 8, 2024
DJ MaxCyte Up Over 27%, on Track for Record Percent Increase -- Data Talk, from 11:31AM ET on Wednesday May 08, 2024 by Dow Jones
11:31AM ET on Wednesday May 08, 2024 by Dow Jones
May 7, 2024
MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance, from 4:06PM ET on Tuesday May 07, 2024 by Dow Jones
4:06PM ET on Tuesday May 07, 2024 by Dow JonesPress Release: MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance, from 4:06PM ET on Tuesday May 07, 2024 by Dow Jones
4:06PM ET on Tuesday May 07, 2024 by Dow Jones
May 3, 2024
*DJ MaxCyte Started at Hold by Deutsche Bank, from 3:15AM ET on Friday May 03, 2024 by Dow Jones
3:15AM ET on Friday May 03, 2024 by Dow Jones
Apr 23, 2024
DJ MaxCyte Price Target Maintained With a $11.00/Share by Stephens & Co., from 11:32AM ET on Tuesday Apr 23, 2024 by Dow Jones
11:32AM ET on Tuesday Apr 23, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
MaxCyte Inc | 474.6M | -13.4x | --- |
Cibus Inc | 468.8M | -1.0x | --- |
908 Devices Inc. | 246.6M | -6.7x | --- |
Pulse Biosciences Inc | 424.7M | -8.8x | --- |
Nano-X Imaging Ltd | 608.4M | -9.9x | --- |
Electromed Inc | 146.0M | 35.0x | +10.79% |
Company Information
MaxCyte, Inc. is a commercial cell engineering company. The Company is focused on providing enabling platform technologies to advance the discovery, development and commercialization of cell therapeutics, including cell and gene therapies, and to support cell-based research and development. It has developed and commercialized its proprietary Flow Electroporation technology, which is used by biopharmaceutical companies in the complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address this rapidly expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of cell-based medicines. The ExPERT family of products includes four instruments, which are known as the ATx, STx, GTx and VLx, as well as a portfolio of proprietary related disposables and consumables.
Contact Information
- Headquarters
- 9713 KEY WEST AVENUE,, SUITE 400ROCKVILLE, MD, United States 20850
- Phone
- 301-517-5556
- Fax
- 301-944-1703
Executives
- Non-Executive Independent Chairman of the Board
- Richard Douglas
- President, Chief Executive Officer, Director
- Maher Masoud
- Chief Financial Officer
- Douglas Swirsky
- Executive Vice President, Global Sales and Marketing
- Thomas Ross
- Executive Vice President - Administration
- Ronald Holtz
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $474.6M |
|---|---|
Revenue (TTM) | $44.1M |
Shares Outstanding | 104.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.35 |
Book Value | $2.23 |
P/E Ratio | -13.4x |
Price/Sales (TTM) | 10.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -107.59% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
